Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Caradrin
2. Desglucotransvaaline
3. Digitalysat
4. Proscillaridin
5. Proscillaridine
6. Rhamnoside, Scillarenin
7. Sandoscill
8. Scillarenin Rhamnoside
9. Scillase
10. Talusin
1. Proscillaridin-a
2. Caradrin
3. Caradrine
4. Nsc7521
5. Cardiovite
6. Proscillan
7. Proscillaridine
8. Proslladin
9. Sandoscill
10. Scillacrist
11. Cardion
12. Carmazon
13. Coratol
14. Procardin
15. Procilan
16. Prostosin
17. Proszin
18. Protasin
19. Solestril
20. Stellarid
21. Talusin
22. Tradenal
23. Urgilan
24. Wirnesin
25. Simeon
26. Herzo Proscillan
27. Purosin-tc
28. 466-06-8
29. Transvaalin, Degluco-
30. 5-[(3s,8r,9s,10r,13r,14s,17r)-14-hydroxy-10,13-dimethyl-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
31. Psc-801
32. Desglucotransvaaline
33. A-32686
34. Scillarenin 3.beta.-rhamnoside
35. Scillarenin, 3.alpha.-l-rhamnopyranoside
36. Rhamnopyranoside, .alpha.-l-
37. Schembl1649544
38. Chembl1977418
39. Hbl0000188
40. Nci60_041645
41. P8334
42. 14-hydroxy-3.beta.-(rhamnosyloxy)bufa-4,22-trienolide
43. Desgluco-transvaalin3.beta.,20,22-trienolide 3-rhamnoside
44. (3beta)-3-[(6-deoxyhexopyranosyl)oxy]-14-hydroxybufa-4,20,22-trienolide
45. [(6-deoxy-.alpha.-l-mannopyranosyl)oxy]-14-hydroxybufa-4,22-trienolide
46. 3.beta.-rhamnosido-14.beta.-hydroxy-.delta.(sup 4,22)-bufatrienolide
47. Wln: L E5 B666 Mutj A1 E1 Iq F- Et6ovj& O- Bt6otj Cq Dq Eq F1
48. Bufa-4,22-trienolide, 3-[(6-deoxy-.alpha.-l-mannopyranosyl)oxy]-14-hydroxy-, (3.beta.)-
49. Bufa-4,22-trienolide, 3.beta.-[(16-deoxy-.alpha.-l-mannosyl)oxy]-14-hydroxy-
50. Bufa-4,22-trienolide, 3.beta.-[(6-deoxy-.alpha.-l-mannopyranosyl)oxy]-14-hydroxy-
51. 5-[(3s,8r,9s,10r,13r,14s,17r)-14-hydroxy-10,13-dimethyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl)oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
| Molecular Weight | 530.6 g/mol |
|---|---|
| Molecular Formula | C30H42O8 |
| XLogP3 | 1.9 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 530.28796829 g/mol |
| Monoisotopic Mass | 530.28796829 g/mol |
| Topological Polar Surface Area | 126 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 1070 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 5 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
ABOUT THIS PAGE
41
PharmaCompass offers a list of Proscillaridin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Proscillaridin manufacturer or Proscillaridin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Proscillaridin manufacturer or Proscillaridin supplier.
PharmaCompass also assists you with knowing the Proscillaridin API Price utilized in the formulation of products. Proscillaridin API Price is not always fixed or binding as the Proscillaridin Price is obtained through a variety of data sources. The Proscillaridin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Talusin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Talusin, including repackagers and relabelers. The FDA regulates Talusin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Talusin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Talusin supplier is an individual or a company that provides Talusin active pharmaceutical ingredient (API) or Talusin finished formulations upon request. The Talusin suppliers may include Talusin API manufacturers, exporters, distributors and traders.
Talusin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Talusin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Talusin GMP manufacturer or Talusin GMP API supplier for your needs.
A Talusin CoA (Certificate of Analysis) is a formal document that attests to Talusin's compliance with Talusin specifications and serves as a tool for batch-level quality control.
Talusin CoA mostly includes findings from lab analyses of a specific batch. For each Talusin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Talusin may be tested according to a variety of international standards, such as European Pharmacopoeia (Talusin EP), Talusin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Talusin USP).
